Norfloxacin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Norfloxacin: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Norfloxacin is a fluoroquinolone antibacterial; the specific ARTG-approved indication text is not on file for this evidence pack, and it is not currently marketed in Australia. The TxGNN model predicts it may be relevant to Hyperamylasemia, but this prediction is currently supported by 0 clinical trials and 0 publications, with no identifiable mechanistic rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file (drug not marketed in Australia; no ARTG indication text available) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Norfloxacin in this evidence pack. Based on general pharmacological knowledge, Norfloxacin belongs to the fluoroquinolone antibacterial class, acting via inhibition of bacterial DNA gyrase and topoisomerase IV.
Hyperamylasemia is a laboratory finding typically associated with pancreatic or salivary gland pathology, and has no established pharmacological connection to antibacterial mechanisms of action. The evidence pack’s own analysis reaches the same conclusion, stating there is no identifiable mechanistic link between Norfloxacin’s antibacterial activity and hyperamylasemia.
No clinical trials or published literature currently link Norfloxacin to hyperamylasemia. This prediction should be treated as a knowledge-graph association arising from the TxGNN model’s embedding space rather than a clinically or mechanistically supported repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN similarity score, there is no mechanistic rationale, no clinical trial, and no published literature connecting Norfloxacin to hyperamylasemia — this is an L5, model-prediction-only signal and does not currently justify further investment.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for Norfloxacin
- TGA/TFDA-sourced Product Information for safety and contraindication review
- Any preclinical or mechanistic rationale connecting fluoroquinolone activity to amylase regulation, if it exists
- Note: among the other 9 predictions in this evidence pack, rank 10 (septicemic plague) has materially stronger support (Evidence Level L4, decision stage S1, “Research Question”) based on Norfloxacin’s known antibacterial activity against Yersinia pestis and CDC/WHO fluoroquinolone-class guidance — this may be a more productive candidate for a separate evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.